Cargando…
Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients
The open-label, phase II clinical trial of antituberculosis therapy (ATT) with or without oral immunomodulator Dzherelo (Immunoxel) was conducted in TB/HIV coinfected, antiretroviral therapy naïve patients to evaluate the effect on CD4 T-lymphocyte counts and viral load. The arm A (n = 20) received...
Autores principales: | Nikolaeva, Lyudmila G, Maystat, Tatyana V, Masyuk, Lilia A, Pylypchuk, Volodymyr S, Volyanskii, Yuri L, Kutsyna, Galyna A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761183/ https://www.ncbi.nlm.nih.gov/pubmed/19920896 |
Ejemplares similares
-
Effect of Immunomodulating Adjuvant Dzherelo (Immunoxel) in HIV Infected Patients Receiving Standard Antiretroviral Therapy
por: Nikolaeva, Lyudmila G, et al.
Publicado: (2009) -
Confronting TB/HIV in the era of increasing anti-TB drug resistance
por: Chakaya, Jeremiah, et al.
Publicado: (2008) -
Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine
por: Lentz, Fabian, et al.
Publicado: (2019) -
TB/HIV : a clinical manual /
por: Harries, A. D.
Publicado: (2004) -
Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)